Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

被引：23

作者：

Munzone, E. ^{[1
]}

Di Pietro, A. ^{[1
]}

Goldhirsch, A. ^{[1
]}

Minchella, I. ^{[1
]}

Verri, E. ^{[1
]}

Rocca, M. Cossu ^{[1
]}

Marenghi, C. ^{[1
]}

Curigliano, G. ^{[1
]}

Radice, D. ^{[2
]}

Adamoli, L. ^{[1
]}

Nole, F. ^{[1
]}

机构：

[1] European Inst Oncol, Div Med Oncol, I-20141 Milan, Italy

[2] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy

来源：

BREAST | 2010年 / 19卷 / 01期

关键词：

Metronomic chemotherapy; Advanced breast cancer; Pegylated liposomal-doxorubicin; PHASE-II TRIAL; CLINICAL BENEFIT; KAPOSIS-SARCOMA; CHEMOTHERAPY; PHARMACOKINETICS; EFFICACY; OVARIAN; CYCLOPHOSPHAMIDE; TOXICITY; SAFETY;

D O I：

10.1016/j.breast.2009.10.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. Patients and methods: In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20 mg/m(2) i.v. every two weeks. Results: 52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18%) had partial responses (PR) and 17 (39%) stable disease (SD), with a clinical benefit (CB) of 45% (95% Cl: 30.3%-59.7%). Nineteen patients (43%) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded. Conclusion: Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast Cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：33 / 37

页数：5

共 29 条

[1] The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial [J].